Drug Search Results
More Filters [+]

Epoprostenol

Alternative Names: epoprostenol, prostacyclin, prostaglandin i2, flolan, veletri
Latest Update: 2024-12-09
Latest Update Note: News Article

Product Description

Epoprostenol is a synthetic analogue of the naturally occurring eicosanoid prostacyclin (prostaglandin I2 or PGI2), which is the main metabolite of arachidonic acid (Sourced from: https://err.ersjournals.com/content/26/143/160055)

Mechanisms of Action: PGI2 Agonist,PA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Czech | Denmark | Estonia | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: Hypertension | Hypertension, Pulmonary | Hypertension | Hypertension, Pulmonary

Known Adverse Events: Dizziness | Headache | Pain Unspecified | Musculoskeletal Pain | Bradycardia | Tachycardia | Hypotension | Abdominal Pain | Chest Pain | Chronic Pain | Dyspnea | Diarrhea | Flushing

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Epoprostenol

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hypertension, Pulmonary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CR109201

P1

Completed

Hypertension, Pulmonary

2023-12-05

21%

Recent News Events